版本:
中国

BRIEF-Chemocentryx receives FDA orphan drug designation for Avacopan in treatment of debilitating kidney disease

March 22 Chemocentryx Inc

* Chemocentryx receives fda orphan drug designation for avacopan in the treatment of debilitating kidney disease c3 glomerulopathy (c3g)

* Chemocentryx inc says plans to initiate a multi-center clinical endpoint study of avacopan for treatment of c3g in first half of 2017

* Chemocentryx inc - u.s. Fda has granted orphan drug designation for avacopan in treatment of patients with c3 glomerulopathy (c3g) Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐